Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 363

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 16I
Chunk 363
---
 classified as held for sale and discontinued operations in our financial statements for the years ended December 31, 2023 and December 31, 2024.
The disposal group mainly contained all assets and liabilities of the our subsidiaries that were fully dedicated to the Jyseleca® business and that were transferred to Alfasigma in the transaction. The divestiture included100% of the shares of the following subsidiaries, including most of the employees: Galapagos Biotech Limited (UK), Galapagos BiopharmaBelgium BV, Galapagos Biopharma GmbH, Galapagos Biopharma Italy S. r. l., Galapagos Biopharma Netherlands B. V., Galapagos Biopharma Spain S. L. U., Galapagos Biopharma Denmark ApS, Galapagos Biopharma Sweden AB, Galapagos Biopharma Finland Oy, Galapagos Biopharma Ireland Ltd., GalapagosBiopharmaNorwayAS, Galapagos Biopharma Austria GmbH. Inaddition, and as part of the same transaction, we transferred all assets, liabilities and employees directly related to the Jyseleca® business but belonging to Galapagos NV or other Galapagos subsidiaries, of which the main asset wa s the worldwideIP relating to Jyseleca®. Our inventories were not considered as part of the disposal group, as these did not transfertoAlfasigmaonclosingofthetransactiononJanuary31,2024but thesewillgradually transfertoAlfasigmaduringthecomingyearsandwewillbeartherisksassociatedwith it as long as it is not transferred.

F-30

Table of Contents

Held for sale assets we re stated at their carrying amount, which is lower than the fair valuelesscoststosell. Weconcludedthattheexpectedpresentvalueofthepurchasepriceto beobtainedfromAlfasigmaforthesaleoftheJyseleca®businessapproximatedthefair value less costs to sell of the disposal group.
The following disclosure illustrates the result from our discontinued operations:
I Disposal of theJyseleca®business
1.1. Consideration received
Year ended December 31, 2024
─────────────────────────────────────────────────────────────────────────────────────────────
(Euro,
Upfront payment received € 50,000
Settlement for net cash and working capital 9,835
Total